Urolithin A‑mediated mitophagy resets NAD+ budgeting by suppressing CD38‑driven consumption and PARP activation

Prof. Layla Zhao (PhD)· Mar 25, 2026

Mechanism: Urolithin A (UA) restores NAD+ levels by activating mitophagy and the AMPK-SIRT1 pathway, which together suppress NAD+ consumption by CD38 and PARP-1. Readout: Readout: CD38 expression drops by 30% and hepatic NAD+ levels rise by 25%, indicating reduced consumption is key to NAD+ restoration.

Hypothesis

Urolithin A (UA) restores NAD+ levels in aged tissues not by boosting synthesis but by lowering NAD+ consumption through a mitophagy‑dependent transcriptional program that suppresses CD38 and PARP activity.

Mechanistic rationale

UA activates AMPK → SIRT1 in intestinal epithelial cells and systemic tissues.
SIRT1 deacetylates NF‑κB p65, reducing its transcriptional drive on the CD38 promoter (see autophagy‑NF‑κB‑NNMT axis)autophagy‑NF‑κB‑NNMT axis.
Lower CD38 expression diminishes the age‑associated NAD+ drain.NAD+ decline mechanisms
Concurrently, UA‑induced mitophagy removes damaged mitochondria, decreasing mitochondrial ROS and thus limiting PARP‑1 activation during DNA‑stress responses.
With both major NAD+‑consuming enzymes curtailed, the cellular NAD+ pool rises despite unchanged precursor supply.
The rise in NAD+ further fuels SIRT1 activity, creating a positive feedback loop that sustains the low‑consumption state.

Testable predictions

In aged mice treated with UA, CD38 mRNA and protein in liver and muscle will drop ≥30% relative to vehicle, while hepatic NAD+ rises ≥25% (measured by LC‑MS).
Pharmacological inhibition of mitophagy (e.g., with Mdivi‑1) or genetic ablation of ATG5 in macrophages will abolish UA‑mediated CD38 suppression and NAD+ restoration.
PARP‑1 activity (assessed by ADP‑ribosylation levels) will fall in UA‑treated animals, correlating with reduced mitochondrial ROS (MitoSOX fluorescence).
Supplementation with nicotinamide riboside (NR) will not further increase NAD+ when UA is given, indicating that the limiting step is consumption, not precursor availability.

Falsifiability

If UA fails to reduce CD38 or PARP activity, or if NAD+ elevation occurs without changes in these enzymes, the hypothesis that UA acts primarily by curbing NAD+ consumption is refuted. Likewise, if blocking mitophagy does not attenuate UA’s effect on NAD+, the proposed link between UA‑driven mitophagy and consumption control is invalid.

Connection to gut‑microbiome axis

The gut‑derived nicotinamide‑to‑nicotinic acid shuttlegut microbiome NAD+ shuttle supplies the precursor pool; UA’s action ensures that this pool is not wasted by excessive CD38‑mediated cleavage, aligning microbial NAD+ recycling with host‑driven consumption control.

Translational implication

Because human NAD+ precursor trials show modest benefitshuman NAD+ precursor trials, targeting consumption pathways with mitophagy‑activating postbiotics like UA may overcome the ceiling observed with simple repletion strategies.

Mechanistic rationale

UA activates AMPK → SIRT1 in intestinal epithelial cells and systemic tissues.

SIRT1 deacetylates NF‑κB p65, reducing its transcriptional drive on the CD38 promoter (see autophagy‑NF‑κB‑NNMT axis)autophagy‑NF‑κB‑NNMT axis.

Lower CD38 expression diminishes the age‑associated NAD+ drain.NAD+ decline mechanisms

Concurrently, UA‑induced mitophagy removes damaged mitochondria, decreasing mitochondrial ROS and thus limiting PARP‑1 activation during DNA‑stress responses.

With both major NAD+‑consuming enzymes curtailed, the cellular NAD+ pool rises despite unchanged precursor supply.

The rise in NAD+ further fuels SIRT1 activity, creating a positive feedback loop that sustains the low‑consumption state.

Testable predictions

In aged mice treated with UA, CD38 mRNA and protein in liver and muscle will drop ≥30% relative to vehicle, while hepatic NAD+ rises ≥25% (measured by LC‑MS).

Pharmacological inhibition of mitophagy (e.g., with Mdivi‑1) or genetic ablation of ATG5 in macrophages will abolish UA‑mediated CD38 suppression and NAD+ restoration.

PARP‑1 activity (assessed by ADP‑ribosylation levels) will fall in UA‑treated animals, correlating with reduced mitochondrial ROS (MitoSOX fluorescence).

Supplementation with nicotinamide riboside (NR) will not further increase NAD+ when UA is given, indicating that the limiting step is consumption, not precursor availability.

Falsifiability